What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?

International Journal of Radiation Oncology Biology Physics

Volumn 61, Issue 4, 2005, Pages 1003-1010

  Feigenberg, Steven J ^a   Hanlon, Alexandra L ^a   Horwitz, Eric M ^a   Uzzo, Robert G ^a   Eisenberg, Debra F ^a   Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Prostate specific antigen; Prostatic neoplasms; Recursive partitioning analysis; Three dimensional conformal radiotherapy

Indexed keywords

BIOCHEMISTRY; DATA REDUCTION; DOSIMETRY; ONCOLOGY; PATIENT TREATMENT; RADIOTHERAPY; REGRESSION ANALYSIS; TUMORS;

FREE FROM BIOCHEMICAL FAILURES (FFBF); LONG-TERM ANDROGEN DEPRIVATION; PROSTRATE-SPECIFIC ANTIGEN (PSA); RECURSIVE PARTITIONING ANALYSIS;

ANTIGENS;

ANDROGEN; LIOTHYRONINE; PROSTATE SPECIFIC ANTIGEN; THYROXINE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; BIOCHEMISTRY; CANCER STAGING; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DATA ANALYSIS; FOLLOW UP; GLEASON SCORE; HEMOCONCENTRATION; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL SOCIETY; MULTIVARIATE ANALYSIS; ONCOLOGY; PATIENT SELECTION; PREDICTION; PREMEDICATION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOLOGY; RANDOMIZATION; REGRESSION ANALYSIS; THYROID DISEASE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; REFERENCE VALUES; REGRESSION ANALYSIS; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC;

EID: 14844321270     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.07.725     Document Type: Article

References (51)

1. M. Bolla, D. Gonzalez, P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
2. M. Bolla, L. Collette, L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
3. M.V. Pilepich, R. Caplan, R.W. Byhardt Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group protocol 85-31 J Clin Oncol 15 1997 1013 1021
4. G.E. Hanks, T.F. Pajak, A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02 J Clin Oncol 21 2003 3972 3978
5. M.V. Pilepich, K. Winter, M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
6. M. Roach III, J. Lu, M.V. Pilepich Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials Int J Radiat Oncol Biol Phys 47 2000 617 627
7. D.B. Chism, A.L. Hanlon, E.M. Horwitz A comparison of the single vs. double high-risk factor stratification systems for prostate cancer treated radiotherapy without androgen deprivation Int J Radiat Oncol Biol Phys 57 2003 S270
8. A.V. D'Amico, R. Whittington, S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
9. A.V. D'Amico, A. Desjardin, A. Chung Assessment of outcome prediction models for localized prostate cancer in patients managed with external beam radiation therapy Semin Urol Oncol 16 1998 153 159
10. A.V. D'Amico, R. Whittington, S.B. Malkowicz Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer Urology 55 2000 572 577
11. A.V. D'Amico, K. Cote, M. Loffredo Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era J Urol 170 2003 S42 S47
12. A.V. D'Amico, K. Cote, M. Loffredo Pretreatment predictors of time to cancer specific death after prostate specific antigen failure J Urol 169 2003 1320 1324
13. A.W. Partin, J. Yoo, H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 110 114
14. A.W. Partin, M.W. Kattan, E.N. Subong Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update JAMA 277 1997 1445 1451
15. G.K. Zagars, A. Pollack Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome Urology 45 1995 476 483
16. M.J. Zelefsky, A. Harrison Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy Urology 49 1997 38 45
17. M.J. Zelefsky, S.A. Leibel, P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500
18. A. Pollack, G.K. Zagars, G. Starkschall Prostate cancer radiation dose response: Results of the M D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
19. M. Roach III, V. Weinberg, P.W. McLaughlin Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate Urology 61 2003 730 735
20. W.U. Shipley, H.D. Thames, H.M. Sandler Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis JAMA 281 1999 1598 1604
21. G. Sanguineti, S. Agostinelli, F. Foppiano Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma Br J Cancer 86 2002 1843 1847
22. S.J. Feigenberg, A.L. Hanlon, E.M. Horwitz Androgen deprivation increases late morbidity in prostate cancer patients treated with 3D conformal radiation therapy Int J Radiat Oncol Biol Phys 57 2003 S176
23. G.E. Hanks, A.L. Hanlon, B. Epstein Dose response in prostate cancer with 8-12 years' follow-up Int J Radiat Oncol Biol Phys 54 2002 427 435
24. International Commission on Radiation Units and Measurements ICRU report 50: Prescribing, recording, and reporting photon beam therapy 1993 ICRU Bethesda
25. J.D. Cox, M.J. Gallagher, E.H. Hammond for the American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy J Clin Oncol 17 1999 1555
26. A.T.J. Ciampi, J.-P. Nakache, B. Asselain Stratification by stepwise regression, correspondence analysis and recursive partition Comput Stat Data Analysis 4 1986 185 204
27. M.R. Segal Regression trees for censored data Biometrics 44 1988 35 47
28. Zhang HP, Singer B. Recursive partitioning in the health sciences. New York: Springer-Verlag; 1999.
29. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
30. Wilcoxon F. Individual comparison by ranking methods. Biometrics 1945;1:80-83.
31. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons; 1980.
32. Lehmann EL. Nonparametrics: Statistical methods based on ranks. San Francisco: Holden-Day; 1975.
33. M. Pilepich Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate: Long-term results of phase III RTOG study 85-31 Int J Radiat Oncol Biol Phys 57 2003 S172 S173
34. E.M. Horwitz, A.L. Hanlon, W.H. Pinover Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques Cancer 92 2001 1281 1287
35. A.L. Zietman, W.U. Shipley, J.J. Coen Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: New insights into outcome from repeat biopsy and prostate specific antigen followup J Urol 152 1994 1806 1812
36. A.L. Zietman, J.J. Coen, W.U. Shipley Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome J Urol 151 1994 640 645
37. G.E. Hanks, W.R. Lee, T.E. Schultheiss Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation J Urol 154 1995 456 459
38. W.R. Lee, G.E. Hanks, T.E. Schultheiss Localized prostate cancer treated by external-beam radiotherapy alone: Serum prostate-specific antigen-driven outcome analysis J Clin Oncol 13 1995 464 469
39. T.M. Pisansky, S.S. Cha, J.D. Earle Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer J Clin Oncol 11 1993 2158 2166
40. T.M. Pisansky, M.J. Kahn, G.M. Rasp A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma Cancer 79 1997 337 344
41. A.V. D'Amico, R. Whittington, S.B. Malkowicz Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: The basis for an adjuvant therapy trial J Clin Oncol 15 1997 1465 1469
42. A.V. D'Amico, R. Whittington, D. Schultz Outcome based staging for clinically localized adenocarcinoma of the prostate J Urol 158 1997 1422 1426
43. H. Ragde, J.C. Blasko, P.D. Grimm Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma Cancer 80 1997 442 453
44. J.C. Blasko, K. Wallner, P.D. Grimm Prostate specific antigen based disease control following ultrasound guided-iodine implantation for stage T1/T2 prostatic carcinoma J Urol 154 1995 1096 1099
45. S.E. Lerner, M.L. Blute, H. Zincke Risk factors for progression in patients with prostate cancer treated with radical prostatectomy Semin Urol Oncol 14 1996 12 21
46. G.K. Zagars, A. Pollack, V.S. Kavadi Prostate-specific antigen and radiation therapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 32 1995 293 306
47. A.W. Partin, S. Piantadosi, M.G. Sanda Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy Urology 45 1995 831 838
48. K. Wallner, J. Roy, L. Harrison Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma J Clin Oncol 14 1996 449 453
49. A. Pollack, L.G. Smith, A.C. von Eschenbach External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era Int J Radiat Oncol Biol Phys 48 2000 507 512
50. A. Pollack, A.L. Hanlon, E.M. Horwitz Prostate cancer radiotherapy dose response: An update of the Fox Chase experience J Urol 171 2004 1132 1136
51. M. Zelefsky, Z. Fuks, H. Chan Ten-year results of dose escalation with 3-dimensional conformal radiotherapy for patients with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 57 2003 S149 S150